[go: up one dir, main page]

GR3026531T3 - Treatment for insulin dependent diabetes. - Google Patents

Treatment for insulin dependent diabetes.

Info

Publication number
GR3026531T3
GR3026531T3 GR980400715T GR980400715T GR3026531T3 GR 3026531 T3 GR3026531 T3 GR 3026531T3 GR 980400715 T GR980400715 T GR 980400715T GR 980400715 T GR980400715 T GR 980400715T GR 3026531 T3 GR3026531 T3 GR 3026531T3
Authority
GR
Greece
Prior art keywords
insulin dependent
treatment
dependent diabetes
diabetes
polypeptide
Prior art date
Application number
GR980400715T
Other languages
English (en)
Inventor
Linda C Burkly
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21848497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3026531(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of GR3026531T3 publication Critical patent/GR3026531T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR980400715T 1993-02-09 1998-04-03 Treatment for insulin dependent diabetes. GR3026531T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2933093A 1993-02-09 1993-02-09
PCT/US1994/001456 WO1994017828A2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes

Publications (1)

Publication Number Publication Date
GR3026531T3 true GR3026531T3 (en) 1998-07-31

Family

ID=21848497

Family Applications (1)

Application Number Title Priority Date Filing Date
GR980400715T GR3026531T3 (en) 1993-02-09 1998-04-03 Treatment for insulin dependent diabetes.

Country Status (13)

Country Link
US (2) US5888507A (el)
EP (1) EP0682529B2 (el)
JP (1) JP3593343B2 (el)
AT (1) ATE161730T1 (el)
AU (1) AU687790B2 (el)
CA (1) CA2155303C (el)
DE (1) DE69407758T3 (el)
DK (1) DK0682529T4 (el)
ES (1) ES2114183T5 (el)
GR (1) GR3026531T3 (el)
HK (1) HK1008731A1 (el)
NZ (1) NZ262615A (el)
WO (1) WO1994017828A2 (el)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843438A (en) 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
ES2289778T3 (es) * 1997-04-18 2008-02-01 Biogen Idec Ma Inc. Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii.
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1113810T3 (da) 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6110109A (en) * 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
SK287328B6 (sk) * 1999-04-22 2010-07-07 Biogen Idec Ma Inc. Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
DK1214091T3 (da) * 1999-09-14 2006-08-28 Biogen Idec Inc Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP2140881B1 (en) 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
PE20040942A1 (es) 2003-01-24 2004-12-28 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2587597A1 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP1833509A4 (en) * 2004-12-03 2008-12-03 Biogen Idec Inc DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
SI3264094T1 (sl) 2005-04-04 2021-04-30 Biogen Ma Inc. Metode za ocenjevanje imunskega odziva na terapevtsko učinkovino
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
DK2034830T3 (da) 2006-05-25 2014-10-27 Biogen Idec Inc Anti-vla-1-antistof til behandling af slagtilfælde
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
EP3808348A1 (en) 2007-09-14 2021-04-21 Biogen MA Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
EP2982695B1 (en) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprising antibodies to lingo or fragments thereof
BRPI1011389A2 (pt) * 2009-04-17 2018-07-10 Biogen Idec Inc método para tratar a leucemia mielógena aguda (aml) em um paciente
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
JP2013507618A (ja) 2009-10-11 2013-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｖｌａ‐４関連アッセイ
MX340683B (es) 2010-04-16 2016-07-21 Biogen Ma Inc Anticuerpos anti-vla-4.
PL3722808T3 (pl) 2010-10-25 2025-02-03 Biogen Ma Inc. Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam
PH12018502221B1 (en) 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US9567392B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
EP2845134A1 (en) 2012-04-20 2015-03-11 Biogen Idec MA Inc. Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
EP2849787A4 (en) 2012-05-14 2016-06-15 Biogen Ma Inc LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISORDERS INVOLVING ENGINE NEURONS
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014028299A1 (en) 2012-08-13 2014-02-20 Biogen Idec Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US20200031924A1 (en) 2016-07-13 2020-01-30 Biogen Ma Inc. Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
MA55298A (fr) 2019-03-11 2022-01-19 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-lingo-1
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
IL113261A (en) † 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
ES2102009T5 (es) * 1992-01-13 2004-12-16 Biogen Inc Tratamiento para el asma.
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
US5843438A (en) * 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4

Also Published As

Publication number Publication date
NZ262615A (en) 1996-02-27
AU687790B2 (en) 1998-03-05
DE69407758D1 (de) 1998-02-12
ATE161730T1 (de) 1998-01-15
US20050208053A1 (en) 2005-09-22
AU6237994A (en) 1994-08-29
WO1994017828A2 (en) 1994-08-18
ES2114183T5 (es) 2006-06-16
WO1994017828A3 (en) 1994-10-13
DE69407758T2 (de) 1998-08-27
ES2114183T3 (es) 1998-05-16
EP0682529B2 (en) 2005-12-28
DK0682529T4 (da) 2006-05-15
CA2155303A1 (en) 1994-08-18
CA2155303C (en) 2010-04-20
DE69407758T3 (de) 2007-05-24
US5888507A (en) 1999-03-30
EP0682529A1 (en) 1995-11-22
JPH08508719A (ja) 1996-09-17
DK0682529T3 (da) 1998-09-07
JP3593343B2 (ja) 2004-11-24
EP0682529B1 (en) 1998-01-07
HK1008731A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
HK1008731A1 (en) Antibody for the treatment of insulin dependent diabetes
GR3023203T3 (en) Treatment for asthma.
CA2115348A1 (en) Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
AU577719B2 (en) Bottle stopper
CA2100745A1 (en) Amylin agonist peptides and uses therefor
AU7410994A (en) Pro-prodrugs, their production and use
EP0655702A3 (en) Correction management for stylus input recognition.
AU7067594A (en) A stabilised phenylalanine ammonia lyase
AU6048496A (en) Separation of hemoglobin on hydroxyapatite using hplc
DK0430200T3 (da) Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation
EP0909562A4 (en) INJECTIONS CONTAINING LIPID A-ANALOG AND METHOD FOR THE PRODUCTION THEREOF
CA2123685A1 (en) Medicament for promoting growth of mammalian nerve
AU2930889A (en) Pharmaceutical preparation for treating immunodeficiency conditions
AU548677B2 (en) Peptides derived from glucagon
IL121203A0 (en) Hypoglycemic and hypolipidemic compounds
EP0362520A3 (de) Ein neues Antibiotikum, Mersacidin, ein Verfahren zur seiner Herstellung und seine Verwendung als Arzneimittel
GB2251188B (en) Drug delivery system comprising a lysophosphoglycerolipid
AU4665193A (en) A process for recovering a recombinant protein, in biologically active form, from a solution containing inactive protein
MY113431A (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
IL110969A0 (en) Process for purifying 1-[n(n2-((s)-ethoxycarbonyl)-3-phenylpropyl)-n6-trifluoroacetyl]-l-lysyl-l-proline
EP0235904A3 (en) Treatment of allergy with thymopentin
EP0193164A3 (en) Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof
ES2102847T3 (es) Procedimiento para la preparacion de bis(2-benzoxazolil)estilbenos.
EP0634168A4 (el)
AU1967199A (en) Kv2.1 antagonists